vTv Therapeutics Stock
vTv Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Paul J. Sekhri
- Employees
- 26
- Market cap
- $105 M
- IPO
- 30/07/2015
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting…
vTv Therapeutics stock: price history
1D
-3.8%
1W
-14.9%
1M
-12.9%
6M
-30.4%
YTD
-33.6%
1Y
+27.7%
2Y
+86.4%
5Y
-54.9%
10Y
-90.3%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~8% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about vTv Therapeutics
Analyst assessment of vTv Therapeutics
PRICE TARGET LOW
US$42.00
CONSENSUS
US$42.00
MEDIAN
US$42.00
PRICE TARGET HIGH
US$42.00
0
STRONG BUY
7
BUY
7
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 14/10/2026
vTv Therapeutics stock metrics
P/E
-241.27
P/B
4.19
EV/EBITDA
-2.86
RETURN ON EQUITY
-16.6%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
52.1%
FLOAT SHARES
2,058,918
AVG. DAILY VOLUME (30D)
34,201
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about vTv Therapeutics stock
What does vTv Therapeutics do?
vTv Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Paul J. Sekhri, the company employs around 26 people.
The IPO was on 30/07/2015; the stock trades on NASDAQ under the ticker VTVT.
What do analysts say about vTv Therapeutics stock?
14 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$42.00, ranging from US$42.00 to US$42.00, with a median of US$42.00.
This is an external assessment, not a statement by Market Jury.
When does vTv Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -8% stronger than usual.
Does vTv Therapeutics pay a dividend?
No, vTv Therapeutics currently does not pay a dividend.
Which stocks are comparable to vTv Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get vTv Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess vTv Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.